Rule 8.1- Tissue Science Lab
28 Marzo 2008 - 8:03AM
UK Regulatory
RNS Number:9864Q
Covidien UK Holding Ltd
28 March 2008
FORM 8.1
DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
(Rules 8.1(a) and (b)(i) of the Takeover Code)
1. KEY INFORMATION
Name of person dealing (Note 1) Covidien UK Holding Ltd (an indirect wholly-owned subsidiary of
Covidien Ltd)
Company dealt in Tissue Science Laboratories plc
Class of relevant security to which the Ordinary shares of 10 pence each
dealings being disclosed relate (Note 2)
Date of dealing 27 March 2008
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
Number (%) Number
(%)
(1) Relevant securities 9,694,245*
(28.0%)
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 9,694,245*
(28.0%)
* All of the 2,685,026 shares purchased on 27 March 2008 related to a Letter of
Intent granted by Hermes Pensions Management to Covidien UK Holding Ltd as
announced at 07.04 on 12 March 2008 under RNS number 8978P. Therefore these
shares are no longer included in the total of irrevocables and letters of intent
that Covidien UK Holding Ltd has received.
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number Number
(%) (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
(c) Rights to subscribe (Note 3)
Class of relevant security: Details
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of securities Price per unit (Note 5)
Purchase 2,685,026* 103.5 pence
(b) Derivatives transactions (other than options)
Product name, Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5)
e.g. CFD
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. Expiry Option money
purchasing, to which the option American,
e.g. call option varying etc. relates (Note 7) price European etc. date paid/received per
unit (Note 5)
(ii) Exercising
Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
(d) Other dealings (including new securities) (Note 4)
Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9)
NO
Date of disclosure 28 March 2008
Contact name Mark Culwick
Telephone number 0121 600 5227
Name of offeree/offeror with which associated n.a.
Specify category and nature of associate status (Note 10) n.a.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCPUUMGWUPRGBM
Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Ott 2023 a Ott 2024
Notizie in Tempo Reale relative a Thinksmart Limited (Borsa di Londra): 0 articoli recenti
Più Tissue Science Articoli Notizie